Literature DB >> 15960901

Psychosocial issues in genital herpes management.

John Green1.   

Abstract

Genital herpes leads to considerable distress in many patients at the time of diagnosis. Most people with recurrences adapt psychologically over time, but some fail to do so, and show continuing psychological morbidity. It is not clear why some people adjust and others do not. Antiviral medication may help to promote adjustment but the evidence is inconclusive. Little is known about the behavioural adjustments that people make, or how they deal with their sexual relationships. Many people fail to disclose to some or all of their sexual partners, particularly casual partners. There are little hard data on the most effective ways to help people adjust to the diagnosis and to help them to reduce the risk of transmission, although what people are told (and the practical advice they are offered) may be important. This article, the first of two papers in this issue to consider the impact of genital herpes, outlines the problems facing people with genital herpes; the second article gives practical guidance for clinicians supporting people with herpes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15960901

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  3 in total

Review 1.  Psychological symptoms associated with genital herpes virus infections: epidemiology and approaches to management.

Authors:  Adrian Mindel; Caron Marks
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  HSV-2 Seroepidemiology and Risk Factors among Iranian Women: A Time to New Thinking.

Authors:  S Asgari; L Chamani-Tabriz; S Asadi; F Fatemi; H Zeraati; M M Akhondi; A Shahnazi
Journal:  Iran Red Crescent Med J       Date:  2011-11-01       Impact factor: 0.611

3.  Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.

Authors:  William P Halford; Ringo Püschel; Brandon Rakowski
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.